Werewolf Therapeutics (NASDAQ:HOWL) Earns Buy Rating from HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 162.24% from the company’s previous close.

Separately, JMP Securities assumed coverage on shares of Werewolf Therapeutics in a research note on Wednesday, April 3rd. They issued a “mkt outperform” rating and a $12.00 price objective on the stock.

Werewolf Therapeutics Stock Down 4.3 %

Shares of NASDAQ HOWL opened at $5.72 on Monday. The business has a 50-day moving average price of $6.18 and a 200 day moving average price of $4.70. The stock has a market cap of $247.96 million, a PE ratio of -5.25 and a beta of 0.71. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 52-week low of $1.57 and a 52-week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.75 million. Equities research analysts forecast that Werewolf Therapeutics will post -1.38 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently modified their holdings of the business. Financial Perspectives Inc grew its holdings in shares of Werewolf Therapeutics by 80.0% in the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after acquiring an additional 3,000 shares during the period. Certuity LLC purchased a new position in Werewolf Therapeutics during the 4th quarter valued at about $39,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Werewolf Therapeutics in the fourth quarter valued at about $87,000. Denali Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $172,000. Finally, PFM Health Sciences LP lifted its stake in Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares in the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.